| Net income | |
| Depreciation and amortization | 23.2M |
| Stock-based compensation expense | 9.52M |
| Loss on disposition of property and equipment | |
| Provision for doubtful accounts | 5.15M |
| Gain on cash surrender value of life insurance policies | |
| Loss on marketable securities classified as trading | |
| Deferred income taxes | |
| Deferred compensation | -6.8M |
| Receivables | |
| Prepaid expenses | |
| Investment in unconsolidated subsidiaries | |
| Income taxes payable | -5.98M |
| Accounts payable and accrued liabilities | -85.13M |
| Other | -2.01M |
| Net cash used in operating activities | |
| Purchase of property and equipment | -32.32M |
| Purchase of marketable securities | -9.53M |
| Proceeds from sales/maturities of marketable securities | 14.14M |
| Payment of contingent consideration from acquisitions | -1.07M |
| Premiums on life insurance policies | -420K |
| Dividends received from unconsolidated subsidiaries | |
| Net cash used in investing activities | |
| Borrowings under life insurance policies | |
| Purchase of common stock | -6.94M |
| Proceeds from exercise of warrants | |
| Proceeds from issuance of common stock upon exercise of employee stock options and in connection with an employee stock purchase plan | 2.61M |
| Tax benefit (expense) from exercise of stock options | |
| Net cash provided (used) in financing activities | |
| Effect of exchange rate changes on cash and cash equivalents | |
| Net decrease in cash and cash equivalents | -23.22M |
| Cash and cash equivalents at beginning of period | 273.25M |
| Cash and cash equivalents at end of period | 250.03M |